Table 2.

Surgical indications and surgical volume of thyroid surgery in 2019 and 2020

Surgical indication	Period I 2019/2020 n (%)	Period II 2019/2020 n (%)	Period III 2019/2020 n (%)	Period IV 2019/2020 n (%)	Total 2019/2020 n (%)
Nodular goiter*	20 (25)/19 (40) p=0.06	16 (20)/0 (0) p=0.001	30 (37)/27 (58) p=0.02	15 (18)/ 1(2) p=0.007	81 (25.9)/47 (18.8) p=0.04
Bethesda 3–4 Cytology	20 (29)/16 (30) p=0.8	10 (14)/0 (0) p=0.004	24 (34)/ 35(66) p=0.004	16 (23)/2 (4) p=0.003	70 (22.4)/53 (21.2) p=0.7
Bethesda 5-6 cytology	25 (26.6)/21 (23) p=0.6	26 (27.6)/3 (3) p=0.0001	30(32) / 51(57) p=0.007	13 (14)/15 (17) p=0.5	94 (30)/90 (36) p=0.1
Recurrent thyroid cancer	2 (9)/2 (10.5) p=0.8	6 (27)/0 (0) p=0.01	11 (50)/15 (79) p=0.05	3 (14)/2 (10.5) p=0.8	22 (7)/19 (7.6) p=0.7
Hyperthyroidism	10 (22)/18 (44) p=0.03	14 (30)/0 (0) p=0.0001	11 (24)/20 (49) p=0.01	11 (24)/3 (7) p=0.03	46 (14.7)/41 (16.4) p=0.5
Total thyroid surgery	77 (25)/76 (30.4) p=0.1	72(23)/3(1.2) p=0.0001	106 (34)/148 (59.2) p=0.0001	58 (18)/23 (9.2) p=0.002	313/250

^*Bilateral or unilateral nodular goiter leading to compressive symptoms with no clinical evidence of malignancy.